603939 益丰药房
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入12,129,9843.48%24,433,16524,062,15522,588,22719,886,396
减:营业总成本10,737,8431.90%22,129,13421,973,89320,616,59718,008,275
    其中:营业成本7,241,9743.78%14,817,33014,408,31113,957,59912,025,564
               财务费用56,579-29.25%142,063173,90386,185104,812
               资产减值损失(46,633)0.30%(111,612)(102,396)(72,634)(56,019)
公允价值变动收益------------
投资收益56,273-18.81%124,748108,12942,3726,869
    其中:对联营企业和合营企业的投资收益------(1)317(11)
营业利润1,446,64313.70%2,453,7242,203,8242,054,7851,885,533
利润总额1,441,76914.10%2,456,3952,182,4472,037,5941,877,487
减:所得税费用372,70217.28%625,369529,665456,663454,061
净利润1,069,06813.03%1,831,0261,652,7821,580,9311,423,426
减:非控股权益105,29060.14%152,544124,206168,946161,585
股东净利润963,7779.51%1,678,4821,528,5771,411,9851,261,841

市场价值指针
每股收益 (元) *0.7908.22%1.3801.2601.1701.260
每股派息 (元) *0.3000.00%0.7000.6500.5000.400
每股净资产 (元) *9.8128.82%9.4138.6649.70211.855
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容